Literature DB >> 16895979

The mechanism of carbamazepine aggravation of absence seizures.

Lige Liu1, Thomas Zheng, Margaret J Morris, Charlott Wallengren, Alison L Clarke, Christopher A Reid, Steven Petrou, Terence J O'Brien.   

Abstract

Carbamazepine (CBZ) aggravates many generalized seizures types, particularly absence seizures, but the mechanisms underlying this are poorly understood. GABA signaling within the reticular nucleus (Rt) and the ventrobasal complex (VB) of the thalamus is critical to the neurophysiology of absence seizures. The hypothesis that CBZ aggravates absence seizures by acting at the VB thalamus via a GABA(A) receptor-mediated mechanism was investigated in a genetic rat model, generalized absence epilepsy rats from Strasbourg (GAERS). Seizure activity was quantified by a 90-min electroencephalogram recording postdrug injection. Intracerebroventricular injections of CBZ (15 microg in 4 microl) resulted in seizure aggravation versus vehicle treatment, with a mean increase in seizure time of 40%. This indicates that CBZ acts directly, rather than via a metabolite, on the brain to aggravate seizures. Seizure aggravation also occurred following bilateral microinjection of CBZ (0.75 microg in 0.2 microl) into the VB (53%) but not following injection into the Rt (-9%). However, seizure aggravation was blocked when the GABA(A) receptor antagonist, bicuculline (BIC, 0.04 microg in 0.2 microl), was coinjected with CBZ into the VB. Injection of BIC alone (versus vehicle) into the VB also blocked seizure aggravation following systemic administration of CBZ (15 mg/kg i.p.). In vitro studies in Xenopus oocytes expressing recombinant GABA(A) receptors demonstrated that CBZ produced a dose-dependent potentiation of the GABA current at a physiological relevant concentration range (1-100 microM). These data demonstrate that CBZ acts at the VB thalamus to aggravate absence seizures in GAERS and that activation of GABA(A) receptors is critical to this effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895979     DOI: 10.1124/jpet.106.104968

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  Seizure aggravation-evidence that oxcarbazepine requires monitoring.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2008 Jul-Aug       Impact factor: 7.500

2.  Augmented currents of an HCN2 variant in patients with febrile seizure syndromes.

Authors:  Leanne M Dibbens; Christopher A Reid; Bree Hodgson; Evan A Thomas; Alison M Phillips; Elena Gazina; Brett A Cromer; Alison L Clarke; Tallie Z Baram; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

3.  Altered intrathalamic GABAA neurotransmission in a mouse model of a human genetic absence epilepsy syndrome.

Authors:  Chengwen Zhou; Li Ding; M Elizabeth Deel; Elizabeth A Ferrick; Ronald B Emeson; Martin J Gallagher
Journal:  Neurobiol Dis       Date:  2014-11-04       Impact factor: 5.996

4.  Cellular and network mechanisms of genetically-determined absence seizures.

Authors:  Didier Pinault; Terence J O'Brien
Journal:  Thalamus Relat Syst       Date:  2007-01-22

5.  N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy.

Authors:  Martina Tallarico; Antonio Leo; Lorenza Guarnieri; Maria Caterina Zito; Carmen De Caro; Ferdinando Nicoletti; Emilio Russo; Andrew Constanti; Giovambattista De Sarro; Rita Citraro
Journal:  Mol Neurobiol       Date:  2022-02-15       Impact factor: 5.590

6.  Seizure exacerbation with anti-seizure medications in adult patients with epilepsy.

Authors:  Maria A Jaramillo; Timothy Pham; Sohail Kamrudin; Rahul Khanna; Atul Maheshwari
Journal:  Epilepsy Res       Date:  2022-02-15       Impact factor: 3.045

7.  Increased thalamic inhibition in the absence seizure prone DBA/2J mouse.

Authors:  Heneu O Tan; Christopher A Reid; Cindy Chiu; Mathew V Jones; Steven Petrou
Journal:  Epilepsia       Date:  2008-02-18       Impact factor: 5.864

8.  Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy.

Authors:  Gabi Dezsi; Ezgi Ozturk; Davor Stanic; Kim L Powell; Hal Blumenfeld; Terence J O'Brien; Nigel C Jones
Journal:  Epilepsia       Date:  2013-03-06       Impact factor: 5.864

9.  Pronounced antiepileptic activity of the subtype-selective GABAA -positive allosteric modulator PF-06372865 in the GAERS absence epilepsy model.

Authors:  Venceslas Duveau; Derek L Buhl; Alexis Evrard; Céline Ruggiero; Betty Mandé-Niedergang; Corinne Roucard; Rachel Gurrell
Journal:  CNS Neurosci Ther       Date:  2018-08-12       Impact factor: 5.243

10.  Long-term valproate treatment increases brain neuropeptide Y expression and decreases seizure expression in a genetic rat model of absence epilepsy.

Authors:  Johanna Elms; Kim L Powell; Leena van Raay; Stefanie Dedeurwaerdere; Terence J O'Brien; Margaret J Morris
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.